1.      Abi-Wardé M, Roda C, Arnoux J, et al. Long-term metabolic follow-up and clinical outcome of 35 patients with maple syrup urine disease. J Inherit Metab Dis. 2017;40(6):783-92.

2.      Aygün F, Kıykım E, Aktuğlu-Zeybek Ç, Zubarioğlu T, Cam H. Treatment of maple syrup urine disease with high-flow hemodialysis in a neonate. Turk J Pediatr. 2019;61(1):107-10.

3.      Berry GT, Heidenreich R, Kaplan P, et al. Branched-chain amino acid-free parenteral nutrition in the treatment of acute metabolic decompensation in MSUD. N Engl J Med. 1991;324(3):175-9.

4.      Billington CJ, Chapman KA, Leon E, et al. Genomic and biochemical analysis of repeatedly observed variants in DBT in individuals with maple syrup urine disease of Central American ancestry. Am J Med Genet A. 2022;188(9):2738-49.

5.      Blackburn P, Gass J, Pinto E, Vairo F, et al. Maple syrup urine disease: mechanisms and management. Appl Clin Genet. 2017;10:57-66.

6.      Brunetti-Pierri N, Lanpher B, Erez A, et al. Phenylbutyrate therapy for maple syrup urine disease. Hum Mol Genet. 2011;20(4):631-40.

7.      Chuang DT, Ku LS, Cox RP. Thiamin-responsive maple syrup urine disease: decreased affinity of the mutant branched-chain $\alpha$-keto acid dehydrogenase for $\alpha$-ketoisovalerate and thiamin pyrophosphate. Proc Natl Acad Sci U S A. 1982;79(10):3300-4.

8.      Çamur S. 199 organik asidemili hastanın klinik, laboratuvar ve demografik özelliklerinin retrospektif olarak değerlendirilmesi. Uzmanlık Tezi. Ankara: Hacettepe Üniversitesi Tıp Fakültesi; 1996.

9.      Deger İ, Çelik M, Taş İ, Samancı S. Continuous veno-venous hemodiafiltration in neonates with maple syrup urine disease. Ther Apher Dial. 2022;26(3):658-66.

10.  Depondt E, Evans S, Daly A, Hendriksz C, Chakrapani AA, Saudubray JM. Breast feeding in IMD. J Inherit Metab Dis. 2006;29:299-303.

11.  Dimou A, Tsimihodimos V, Bairaktari E. The critical role of the branched chain amino acids catabolism-regulating enzymes BCAT and BCKD in human pathophysiology. Int J Mol Sci. 2022;23(7):4022.

12.  Evans S, Daly A, MacDonald J, Pinto A, MacDonald A. Fifteen years of using a second stage protein substitute for weaning in phenylketonuria: a retrospective study. J Hum Nutr Diet. 2018;31(3):349-56.

13.  Frazier DM, Allgeier C, Homer C, et al. Nutrition management guideline for maple syrup urine disease: an evidence- and consensus-based approach. Mol Genet Metab. 2014;112(3):210-7.

14.  Grünert SC, Rosenbaum-Fabian S, Schumann A, et al. Successful pregnancy in maple syrup urine disease: a case report and review. Nutr J. 2018;17:51.

15.  Hassan SA, Gupta V. Maple syrup urine disease. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.

16.  Heldt K, Schwahn B, Marquardt I, Grotzke M, Wendel U. Diagnosis of MSUD by newborn screening allows early intervention without extraneous detoxification. Mol Genet Metab. 2005;84(4):313-6.

17.  Herden U, Grabhorn E, Santer R, et al. Surgical aspects of liver transplantation and domino liver transplantation in Maple Syrup Urine Disease: analysis of 15 donor-recipient pairs. Liver Transpl. 2019;25(6):889-900.

18.  Hoffmann B, Helbling C, Schadewaldt P, Wendel U. Impact of longitudinal plasma leucine levels on intellectual outcome in patients with classic MSUD. Pediatr Res. 2006;59(1):17-20.

19.  Jouvet P, Jugie M, Rabier D, et al. Combined nutritional support and continuous extracorporeal removal therapy in the severe acute phase of maple syrup urine disease. Intensive Care Med. 2001;27(11):1798-806.

20.  Lee JY, Chiong MA, Estrada SC, et al. Maple syrup urine disease: clinical profile of 47 Filipino patients. J Inherit Metab Dis. 2008;31(S2):281-5.

21.  Liu Q, Li F, Zhou J, et al. Neonatal maple syrup urine disease: case report and literature review. Medicine (Baltimore). 2022;101(50):e32174.

22.  Lynch CJ, Adams SH. Branched-chain amino acids in metabolic signalling and insulin resistance. Nat Rev Endocrinol. 2014;10(12):723-36.

23.  Mazariegos GV, Morton DH, Sindhi R, et al. Liver transplantation for classical MSUD: long-term follow-up in 37 patients. J Pediatr. 2012;160(1):116-21.

24.  Morton DH, Strauss KA, Robinson DL, Puffenberger EG, Kelley RI. Diagnosis and treatment of maple syrup disease: a study of 36 patients. Pediatrics. 2002;109(6):999-1008.

25.  Nyhan WL, Rice-Kelts M, Klein J, Barshop BA. Treatment of the acute crisis in maple syrup urine disease. Arch Pediatr Adolesc Med. 1998;152(6):593-8.

26.  Pappas K, Fabie NAV, Feldman GL. Child with suspected metabolic disorder. In: Kamat DM, Sivaswamy L, editors. Symptom-Based Approach to Pediatric Neurology. Cham: Springer; 2022. p. 639-52.

27.  Podebrad F, Heil M, Reichert S, Mosandl A, Sewell AC, Böhles H. Sotolone—the odour of maple syrup urine disease. J Inherit Metab Dis. 1999;22(2):107-14.

28.  Puliyanda DP, Harmon WE, Peterschmitt MJ, Irons M, Somers MJG. Utility of hemodialysis in maple syrup urine disease. Pediatr Nephrol. 2002;17(4):239-42.

29.  Rezvani I, Rosenblatt DS. Valine, leucine, isoleucine, and related organic acidemias. In: Nelson Textbook of Pediatrics. 17th ed. Philadelphia: WB Saunders; 2004. p. 409-18.

30.  Rodan LH, Aldubayan SH, Berry GT, Levy HL. Acute illness protocol for maple syrup urine disease. Pediatr Emerg Care. 2018;34(1):64-7.

31.  Rostampour N, Dalili S, Moravej H, et al. Comprehensive Iranian guidelines for the diagnosis and management of maple syrup urine disease. Orphanet J Rare Dis. 2025;20(1):8.

32.  Schönberger S, Schweiger B, Schwahn B, Schwarz M, Wendel U. Dysmyelination in the brain of adolescents and young adults with maple syrup urine disease. Mol Genet Metab. 2004;82(1):69-75.

33.  Servais A, Arnoux JB, Lamy C, et al. Treatment of acute decompensation of maple syrup urine disease in adult patients with a new parenteral amino-acid mixture. J Inherit Metab Dis. 2013;36(6):939-44.

34.  Simon E, Flaschker N, Schadewaldt P, Langenbeck U, Wendel U. Variant maple syrup urine disease—the entire spectrum. J Inherit Metab Dis. 2006;29(6):716-24.

35.  Strauss KA, Carson VJ, Soltys K, et al. Branched-chain α-ketoacid dehydrogenase deficiency (maple syrup urine disease): treatment, biomarkers, and outcomes. Mol Genet Metab. 2020;129(3):193-206.

36.  Strauss KA, Mazariegos GV, Sindhi R, et al. Elective liver transplantation for the treatment of classical maple syrup urine disease. Am J Transplant. 2006;6(3):557-64.

37.  Strauss KA, Morton DH. Branched-chain ketoacyl dehydrogenase deficiency: Maple syrup disease. Curr Treat Options Neurol. 2003;5(4):329-41.

38.  Strauss KA, Wardley B, Robinson D, et al. Classical maple syrup urine disease and brain development: principles of management and formula design. Mol Genet Metab. 2010;99(4):333-45.

39.  Sundaram SS, Alonso EM, Whitington PF. Liver transplantation in neonates. Liver Transpl. 2003;9(8):783-8.

40.  Suryawan A, Hawes JW, Harris RA, Shimomura Y, Jenkins AE, Hutson SM. A molecular model of human branched-chain amino acid metabolism. Am J Clin Nutr. 1998;68(1):72-81.

41.  Young VR. Kinetics of human amino acid metabolism: nutritional implications and some lessons. Am J Clin Nutr. 1987;46(5):709-25.

42.  Zhang S, Zeng X, Ren M, Mao X, Qiao S. Novel metabolic and physiological functions of branched-chain amino acids: a review. J Anim Sci Biotechnol. 2017;8:10.